Director Steven Rubin acquires 10,000 Entera Bio (ENTX) shares

Rhea-AI Filing Summary

Entera Bio director Steven D. Rubin reported a share purchase. On February 9, 2026, he bought 10,000 Ordinary Shares of Entera Bio Ltd. at $1.20 per share.

Following this transaction, Rubin beneficially owns 10,000 Ordinary Shares, all held in direct ownership.

Insider Trade Summary

Net Buyer: 10,000 shares ($12,000)

Net Buy 1 txn

Insider Rubin Steven D

Role Director

Bought 10,000 shs ($12K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares, par value NIS 0.0000769 per share	10,000	$1.20	$12K

Holdings After Transaction: Ordinary Shares, par value NIS 0.0000769 per share — 10,000 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rubin Steven D

(Last) (First) (Middle)

KIRYAT HADASSAH,

MINRAV BUILDING, 5TH FLOOR

(Street)

JERUSALEM L3 9112002

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Entera Bio Ltd. [ [ENTX] ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares, par value NIS 0.0000769 per share	02/09/2026		P		10,000	A	$1.2	10,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Dana Yaacov-Garbeli, Attorney-in-fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does this Entera Bio (ENTX) Form 4 filing report?

The Form 4 reports that director Steven D. Rubin purchased 10,000 Entera Bio Ordinary Shares. The transaction occurred on February 9, 2026 at $1.20 per share, and it updates his reported beneficial ownership position in the company’s stock.

How many Entera Bio (ENTX) shares did Steven D. Rubin buy?

Steven D. Rubin bought 10,000 Ordinary Shares of Entera Bio. The transaction is reported as an acquisition, coded “P” for purchase, and it increased his beneficially owned position to a total of 10,000 Ordinary Shares after the transaction.

At what price were the Entera Bio (ENTX) shares purchased in this Form 4?

The Entera Bio shares were purchased at $1.20 per Ordinary Share. This per-share price applies to the entire 10,000-share transaction reported, reflecting the consideration Rubin paid on February 9, 2026 for the newly acquired Ordinary Shares.

What is Steven D. Rubin’s ownership in Entera Bio (ENTX) after the transaction?

After the reported transaction, Steven D. Rubin beneficially owns 10,000 Entera Bio Ordinary Shares. The Form 4 indicates these shares are held with direct ownership, meaning the position is reported in his own name rather than through an intermediate entity.

Is the reported Entera Bio (ENTX) Form 4 transaction a purchase or sale?

The transaction is a purchase of Entera Bio shares. It is coded “P” for purchase in the Form 4, and shows Steven D. Rubin acquiring 10,000 Ordinary Shares at $1.20 per share, increasing his directly held beneficial ownership to 10,000 shares.

What type of security did Steven D. Rubin acquire in Entera Bio (ENTX)?

He acquired Ordinary Shares of Entera Bio Ltd., each with a par value of NIS 0.0000769. The Form 4 shows a non-derivative equity transaction, distinguishing these shares from options, warrants, or other derivative securities that might be reported separately.